Ankit Mahadevia
2022
In 2022, Ankit Mahadevia earned a total compensation of $4.2M as Former President and Chief Executive Officer at Spero Therapeutics, a 13% decrease compared to previous year.
Compensation breakdown
Bonus | $254,000 |
---|---|
Non-Equity Incentive Plan | $342,900 |
Option Awards | $1,499,324 |
Salary | $633,750 |
Stock Awards | $1,499,998 |
Other | $9,733 |
Total | $4,239,705 |
Mahadevia received $1.5M in stock awards, accounting for 35% of the total pay in 2022.
Mahadevia also received $254K in bonus, $342.9K in non-equity incentive plan, $1.5M in option awards, $633.8K in salary and $9.7K in other compensation.
Rankings
In 2022, Ankit Mahadevia's compensation ranked 806th out of 5,694 executives tracked by ExecPay. In other words, Mahadevia earned more than 85.8% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 806 | 86th |
Manufacturing | 365 | 88th |
Chemicals And Allied Products | 122 | 91st |
Drugs | 109 | 92nd |
Pharmaceutical Preparations | 80 | 92nd |
Mahadevia's colleagues
We found two more compensation records of executives who worked with Ankit Mahadevia at Spero Therapeutics in 2022.
News
Spero Therapeutics CEO Ankit Mahadevia's 2022 pay slips 13% to $4.2M
September 1, 2023
Spero Therapeutics CEO Ankit Mahadevia's 2021 pay jumps 130% to $4.9M
August 5, 2022
Spero Therapeutics CEO Ankit Mahadevia's 2019 pay jumps 148% to $1.8M
September 30, 2020
Spero Therapeutics Chief Medical Officer David Melnick receives $1.6M in 2018
April 26, 2019